Hemoadsorption therapy for calcium channel blocker overdose: A case report
Background: Modern resin hemoadsorption/hemoperfusion (HP) for calcium channel blocker (CCB) overdose is yet to be reported. The characteristics of CCBs make them unamenable to removal by haemodiafiltration or charcoal hemoperfusion, however, elimination, using styrene bead adsorption in an ex-vivo model has been demonstrated. Its clinical use is described.Case report: A male in his twenties was admitted with shock into the Intensive Care Unit (ICU), following an overdose of amlodipine and risperidone. (Source: The Journal of Emergency Medicine)
Source: The Journal of Emergency Medicine - December 8, 2023 Category: Emergency Medicine Authors: Shahed Omar, Pano Parris, Chloe Rose Gurke Tags: Selected Topics: Toxicology Source Type: research
The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}
Hypertension increases the risk of cardiovascular disease. Uncontrolled nocturnal blood pressure is prevalent in patients taking antihypertensive medication, with an incidence rate of 30 –60%. Although chronoth... (Source: Trials)
Source: Trials - November 28, 2023 Category: General Medicine Authors: Mengzhuo Xu, Xin Zhang, Runyu Ye, Xueting Liu, Lirong Sun, Shanshan Jia, Zhipeng Zhang, Xinran Li, Ziqiong Wang, Hang Liao, Rufeng Shi, Kai Liu, Si Wang, Qingtao Meng and Xiaoping Chen Tags: Study protocol Source Type: research
Pharmacokinetics and Bioequivalence of Amlodipine Besylate Tablet in Healthy Chinese Volunteers Under Fasting and Fed Conditions
AbstractThe purpose of this study was to compare the blood concentration and pharmacokinetic (PK) parameters of 2 formulations under fasting and ed conditions in healthy Chinese volunteers and to evaluate whether the 2 preparations were bioequivalent. This trial screened 170 subjects. Thirteen subjects were assigned to the fasting trial and 18 subjects to the fed trial; 1 subject in the fed trial group was automatically withdrawn for personal reasons. Two cycles had a 14-day washout period. This clinical study was a bioequivalence study, with PK parameters as end point indicators. The bioequivalence PK parameters were the ...
Source: Clinical Pharmacology in Drug Development - November 24, 2023 Category: Drugs & Pharmacology Authors: Liyuan Tang,
Yanrong Wang,
Ran Chen,
Yuanyuan He,
Ying Liu,
Na Wang,
Xiaoyan Sun,
Jingya Song Tags: Original Article Source Type: research
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia
CONCLUSIONS: The available evidence suggests that calcium channel blockers may reduce MIC and may increase liver T2* values in people with transfusion-dependent beta thalassaemia. Longer-term multicentre RCTs are needed to assess the efficacy and safety of calcium channel blockers for myocardial iron overload, especially in younger children. Future trials should also investigate the role of baseline MIC in the response to calcium channel blockers, and include a cost-effectiveness analysis.PMID:37975597 | PMC:PMC10655499 | DOI:10.1002/14651858.CD011626.pub3 (Source: Cancer Control)
Source: Cancer Control - November 17, 2023 Category: Cancer & Oncology Authors: Zahra Ali Padhani Manesh Kumar Gangwani Alina Sadaf Babar Hasan Steven Colan Najveen Alvi Jai K Das Source Type: research
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia
CONCLUSIONS: The available evidence suggests that calcium channel blockers may reduce MIC and may increase liver T2* values in people with transfusion-dependent beta thalassaemia. Longer-term multicentre RCTs are needed to assess the efficacy and safety of calcium channel blockers for myocardial iron overload, especially in younger children. Future trials should also investigate the role of baseline MIC in the response to calcium channel blockers, and include a cost-effectiveness analysis.PMID:37975597 | PMC:PMC10655499 | DOI:10.1002/14651858.CD011626.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - November 17, 2023 Category: General Medicine Authors: Zahra Ali Padhani Manesh Kumar Gangwani Alina Sadaf Babar Hasan Steven Colan Najveen Alvi Jai K Das Source Type: research
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia
CONCLUSIONS: The available evidence suggests that calcium channel blockers may reduce MIC and may increase liver T2* values in people with transfusion-dependent beta thalassaemia. Longer-term multicentre RCTs are needed to assess the efficacy and safety of calcium channel blockers for myocardial iron overload, especially in younger children. Future trials should also investigate the role of baseline MIC in the response to calcium channel blockers, and include a cost-effectiveness analysis.PMID:37975597 | PMC:PMC10655499 | DOI:10.1002/14651858.CD011626.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - November 17, 2023 Category: General Medicine Authors: Zahra Ali Padhani Manesh Kumar Gangwani Alina Sadaf Babar Hasan Steven Colan Najveen Alvi Jai K Das Source Type: research
Cancer Stem Cells of Hepatocellular Carcinoma Are Suppressed by the Voltage-gated Calcium Channel Inhibitor Amlodipine
CONCLUSION: CACNG4 plays a role in maintaining CSCs, and its inhibitor, amlodipine, could potentially be a targeted therapeutic agent against HCC.PMID:37909988 | DOI:10.21873/anticanres.16682 (Source: Cell Research)
Source: Cell Research - November 1, 2023 Category: Cytology Authors: Atsushi Shiozaki Kento Kurashima Michihiro Kudou Hiroki Shimizu Toshiyuki Kosuga Kenichi Takemoto Tomohiro Arita Hirotaka Konishi Yusuke Yamamoto Ryo Morimura Shuhei Komatsu Hisashi Ikoma Takeshi Kubota Hitoshi Fujiwara Eigo Otsuji Source Type: research
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial
CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.PMID:37905403 | DOI:10.1161/CIRCULATIONAHA.123.066680 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Aish Sinha Haseeb Rahman Abdel Douiri Ozan M Demir Kalpa De Silva Brian Clapp Ian Webb Ankur Gulati Pedro Pinho Utkarsh Dutta Howard Ellis Ajay M Shah Amedeo Chiribiri Michael Marber Andrew J Webb Divaka Perera Source Type: research
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial
CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.PMID:37905403 | DOI:10.1161/CIRCULATIONAHA.123.066680 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Aish Sinha Haseeb Rahman Abdel Douiri Ozan M Demir Kalpa De Silva Brian Clapp Ian Webb Ankur Gulati Pedro Pinho Utkarsh Dutta Howard Ellis Ajay M Shah Amedeo Chiribiri Michael Marber Andrew J Webb Divaka Perera Source Type: research
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial
CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.PMID:37905403 | DOI:10.1161/CIRCULATIONAHA.123.066680 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Aish Sinha Haseeb Rahman Abdel Douiri Ozan M Demir Kalpa De Silva Brian Clapp Ian Webb Ankur Gulati Pedro Pinho Utkarsh Dutta Howard Ellis Ajay M Shah Amedeo Chiribiri Michael Marber Andrew J Webb Divaka Perera Source Type: research
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial
CONCLUSIONS: Among phenotypically similar patients with angina with nonobstructive coronary arteries, only those with an impaired CFR derive benefit from anti-ischemic therapy. These findings support measurement of CFR to diagnose and guide management of this otherwise heterogeneous patient group.PMID:37905403 | DOI:10.1161/CIRCULATIONAHA.123.066680 (Source: Circulation)
Source: Circulation - October 31, 2023 Category: Cardiology Authors: Aish Sinha Haseeb Rahman Abdel Douiri Ozan M Demir Kalpa De Silva Brian Clapp Ian Webb Ankur Gulati Pedro Pinho Utkarsh Dutta Howard Ellis Ajay M Shah Amedeo Chiribiri Michael Marber Andrew J Webb Divaka Perera Source Type: research
